ATE305921T1 - Neue analoga von 16-hydroxyeicosatetraensäure - Google Patents

Neue analoga von 16-hydroxyeicosatetraensäure

Info

Publication number: ATE305921T1
Authority: AT; Austria
Prior art keywords: hete; hydroxyeicosatetraenic; acid; agonists; new analogue
Prior art date: 1998-05-15

Application number

AT99924250T

Other languages

English (en)

Inventor

John R Falck

Martin M Bednar

Cordell E Gross

Michael Balazy

Original Assignee

Univ Vermont

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-15

Filing date

1999-05-14

Publication date

2005-10-15

1999-05-14 Application filed by Univ Vermont, Univ Texas filed Critical Univ Vermont

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE305921T1 publication Critical patent/ATE305921T1/de

Links

DKKVWVTZCIIJMT-UHFFFAOYSA-N 16-hydroxyicosa-2,4,6,8-tetraenoic acid Chemical class CCCCC(O)CCCCCCC=CC=CC=CC=CC(O)=O DKKVWVTZCIIJMT-UHFFFAOYSA-N 0.000 title 1
JEKNPVYFNMZRJG-UFINWASNSA-N 16-HETE Chemical compound CCCCC(O)\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JEKNPVYFNMZRJG-UFINWASNSA-N 0.000 abstract 3
239000000556 agonist Substances 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
210000000440 neutrophil Anatomy 0.000 abstract 2
150000000295 16-HETE derivatives Chemical class 0.000 abstract 1
206010014498 Embolic stroke Diseases 0.000 abstract 1
238000004220 aggregation Methods 0.000 abstract 1
230000002776 aggregation Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
239000003527 fibrinolytic agent Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
229960000103 thrombolytic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT99924250T 1998-05-15 1999-05-14 Neue analoga von 16-hydroxyeicosatetraensäure ATE305921T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8560298P	1998-05-15	1998-05-15
PCT/US1999/010728 WO1999059964A1 (en)	1998-05-15	1999-05-14	Novel analogs of 16-hydroxyeicosatetraenoic acid

Publications (1)

Publication Number	Publication Date
ATE305921T1 true ATE305921T1 (de)	2005-10-15

Family

ID=22192722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99924250T ATE305921T1 (de)	1998-05-15	1999-05-14	Neue analoga von 16-hydroxyeicosatetraensäure

Country Status (7)

Country	Link
US (3)	US6359158B1 (de)
EP (1)	EP1077936B1 (de)
JP (1)	JP2002515480A (de)
AT (1)	ATE305921T1 (de)
CA (1)	CA2332272A1 (de)
DE (1)	DE69927582D1 (de)
WO (1)	WO1999059964A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002515480A (ja) *	1998-05-15	2002-05-28	ユニバーシティオブバーモント	１６−ヒドロキシエイコサテトラエン酸の新規アナログ
WO2001034550A2 (en)	1999-11-09	2001-05-17	Alcon Universal Ltd.	15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
WO2002022163A1 (en) *	2000-09-13	2002-03-21	Chugai Seiyaku Kabushiki Kaisha	Remedies for ischemic diseases
CN1582269A (zh) *	2001-09-14	2005-02-16	大正制药株式会社	羟基二十碳烯酸类似物
CA2502357A1 (en) *	2002-10-17	2004-04-29	Decode Genetics Ehf.	Susceptibility gene for myocardial infarction; methods of treatment
US7851486B2 (en)	2002-10-17	2010-12-14	Decode Genetics Ehf.	Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004051914A1 (en) *	2002-12-03	2004-06-17	Koninklijke Philips Electronics N.V.	A simplified decoder for a bit interleaved cofdm-mimo system
WO2004072013A1 (ja) *	2003-02-14	2004-08-26	Taisho Pharmaceutical Co.,Ltd.	ヒドロキシエイコサジエン酸化合物
AU2004214938B2 (en) *	2003-02-26	2008-11-06	Johns Hopkins University	Glutamate transport modulatory compounds and methods
WO2004080389A2 (en) *	2003-03-07	2004-09-23	Taisho Pharmaceutical Co., Ltd.	Hydroxyeicosadienamide compounds
AU2004285473A1 (en) *	2003-10-21	2005-05-12	Johns Hopkins University	Neuroprotection with beta-lactam compounds
CN101022796B (zh)	2004-07-14	2013-02-27	炎症研究中心有限公司	抑制肿瘤转移的方法
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
JP2016538288A (ja) *	2013-11-15	2016-12-08	ディグニティサイエンシスリミテッド	多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
US11690825B2 (en)	2016-03-09	2023-07-04	Board Of Regents, The University Of Texas System	20-HETE receptor (GPR75) antagonists and methods of use
US12433864B2 (en)	2019-06-03	2025-10-07	Migal Galilee Research Institute Ltd.	5,6-diHETE lactone for treatment of microvascular dysfunction
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111803482B (zh) *	2020-07-31	2021-09-10	中国农业科学院特产研究所	鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5164381A (en)	1986-05-29	1992-11-17	Ortho Pharmaceutical Corporation	Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5256538A (en)	1991-03-08	1993-10-26	Board Of Regents, The University Of Texas System	Detection of early platelet activation and prediagnosis of thrombotic events
US5334736A (en)	1991-05-16	1994-08-02	University Of Texas System Board Of Regents	Functionalizing carbohydrate derivatives by base-induced β-eliminatiom forming bioactive derivatives containing hydroxy-diene subunits
US5273999A (en)	1991-09-10	1993-12-28	Hoffmann-La Roche Inc.	Carboxylic acid leukotriene B4 antagonists
JP3188457B2 (ja)	1992-03-07	2001-07-16	森永乳業株式会社	免疫促進剤
US5324743A (en)	1992-12-10	1994-06-28	Eli Lilly And Company	Leukotriene B4 antagonists
US5527890A (en)	1993-04-16	1996-06-18	Glycomed Incorporated	Derivatives of triterpenoid acids and uses thereof
US5612377A (en)	1994-08-04	1997-03-18	Minnesota Mining And Manufacturing Company	Method of inhibiting leukotriene biosynthesis
US5753702A (en) *	1996-05-22	1998-05-19	University Of Vermont	Arachidonic acid metabolite, 16-hete
JP2002515480A (ja) *	1998-05-15	2002-05-28	ユニバーシティオブバーモント	１６−ヒドロキシエイコサテトラエン酸の新規アナログ
CN1582269A (zh)	2001-09-14	2005-02-16	大正制药株式会社	羟基二十碳烯酸类似物

1999
- 1999-05-14 JP JP2000549583A patent/JP2002515480A/ja not_active Withdrawn
- 1999-05-14 DE DE69927582T patent/DE69927582D1/de not_active Expired - Lifetime
- 1999-05-14 US US09/312,159 patent/US6359158B1/en not_active Expired - Fee Related
- 1999-05-14 AT AT99924250T patent/ATE305921T1/de not_active IP Right Cessation
- 1999-05-14 CA CA002332272A patent/CA2332272A1/en not_active Abandoned
- 1999-05-14 WO PCT/US1999/010728 patent/WO1999059964A1/en not_active Ceased
- 1999-05-14 EP EP99924250A patent/EP1077936B1/de not_active Expired - Lifetime
2001
- 2001-11-09 US US10/044,424 patent/US6562988B2/en not_active Expired - Fee Related
2003
- 2003-02-27 US US10/375,287 patent/US6903135B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6359158B1 (en)	2002-03-19
US20030176509A1 (en)	2003-09-18
CA2332272A1 (en)	1999-11-25
US6903135B2 (en)	2005-06-07
EP1077936B1 (de)	2005-10-05
US6562988B2 (en)	2003-05-13
JP2002515480A (ja)	2002-05-28
DE69927582D1 (de)	2006-02-16
US20020165262A1 (en)	2002-11-07
WO1999059964A1 (en)	1999-11-25
EP1077936A1 (de)	2001-02-28

Legal Events

Date	Code	Title	Description
2006-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE305921T1 (de)	2005-10-15	Neue analoga von 16-hydroxyeicosatetraensäure
EA200200806A1 (ru)	2003-02-27	Предупреждение потери и восстановление костной массы некоторыми агонистами простагландина
DK1135153T3 (da)	2005-08-15	Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
EE04911B1 (et)	2007-10-15	Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
WO2003037271A3 (en)	2003-10-16	Compounds, pharmaceutical compositions and methods of use therefor
NO971889L (no)	1997-06-23	Forbindelser og sammensetninger for levering av aktive midler
EA200100872A1 (ru)	2002-02-28	Композиция валдекоксиба
EE9800173A (et)	1998-12-15	Gonadotropiini riliisinghormooni antagonistid
PL361341A1 (pl)	2004-10-04	Nowa kompozycja farmaceutyczna
IT1282352B1 (it)	1998-03-20	Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
IT1288290B1 (it)	1998-09-11	Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
YU7797A (sh)	2000-10-30	Kombinovana terapija za osteoporozu
DE69507614D1 (de)	1999-03-11	3-amino-2-oxo-piperidinessigsäurederivate, die eine argininnachahmende verbindung, mit enzyminhibitorischen wirkung enthalten
IL140930A0 (en)	2002-02-10	Compounds and compositions for delivering active agents
ITFI930247A1 (it)	1995-06-03	Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
MXPA04000456A (es)	2004-03-18	Analogos de prostaglandina como agonistas del receptor ep4.
RU95106649A (ru)	1997-01-10	Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
PL367094A1 (en)	2005-02-21	Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
ATE311373T1 (de)	2005-12-15	Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
ID28510A (id)	2001-05-31	Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
DE69836678D1 (de)	2007-02-01	Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
SE0102055D0 (sv)	2001-06-08	New Compounds
IT1261471B (it)	1996-05-23	Composizione farmaceutica per somministrazione rettale nel trattamentodi cefalea e relativo metodo di preparazione ed impiego.
DK0917460T3 (da)	2002-03-25	Cyclosporin-formulering
ITRM950273A0 (it)	1995-04-28	Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.